↓ Skip to main content

Effect of Sulforaphane on Growth Inhibition in Human Brain Malignant Glioma GBM 8401 Cells by Means of Mitochondrial- and MEK/ERK-Mediated Apoptosis Pathway

Overview of attention for article published in Cell Biochemistry and Biophysics, May 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

facebook
1 Facebook page
reddit
1 Redditor

Readers on

mendeley
26 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of Sulforaphane on Growth Inhibition in Human Brain Malignant Glioma GBM 8401 Cells by Means of Mitochondrial- and MEK/ERK-Mediated Apoptosis Pathway
Published in
Cell Biochemistry and Biophysics, May 2012
DOI 10.1007/s12013-012-9360-3
Pubmed ID
Authors

Tzuu-Yuan Huang, Weng-Cheng Chang, Miin-Yau Wang, Yun-Ru Yang, Yi-Chiang Hsu

Abstract

In recent studies, sulforaphane (SFN) has been seen to demonstrate antioxidant and anti-tumor activities as well as potent chemopreventive action against cancer. The present study investigates the anti-proliferation (using MTT assay, SFN demonstrated cytotoxic activity against GBM 8401 cell with IC(50) values at 35.52 μM) and induced apoptosis of SFN 24-h treatment in the cells of human brain malignant glioma GBM 8401 cells. We studied the MMP, caspase, MEK/ERK activation, and NF-κB transcription factor activity. Our results indicate that SFN inhibits cell proliferation as well as the activation of apoptosis in GBM 8401 cells. Both effects increased in proportion to the dosage of SFN, and apoptosis was induced via mitochondria- and caspase-dependent pathways. Daily s.c. injections of SFN for 3 weeks in severe combined immunodeficient mice (SCID) with GBM8401 s.c. tumors resulted in a decrease in mean tumor weight of 69-75 % compared with vehicle-treated controls. Our findings suggest that, in addition to the known effects on cancer prevention, SFN may provide antitumor activity in established malignant glioma.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 26 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 19%
Researcher 5 19%
Student > Master 3 12%
Student > Bachelor 2 8%
Student > Doctoral Student 2 8%
Other 2 8%
Unknown 7 27%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 23%
Medicine and Dentistry 6 23%
Immunology and Microbiology 2 8%
Agricultural and Biological Sciences 2 8%
Environmental Science 1 4%
Other 2 8%
Unknown 7 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2017.
All research outputs
#18,308,895
of 22,668,244 outputs
Outputs from Cell Biochemistry and Biophysics
#473
of 910 outputs
Outputs of similar age
#126,168
of 163,487 outputs
Outputs of similar age from Cell Biochemistry and Biophysics
#6
of 11 outputs
Altmetric has tracked 22,668,244 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 910 research outputs from this source. They receive a mean Attention Score of 2.1. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,487 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.